From a drug-discovery standpoint because inhibition of the PTPRH/CNKSR1 complex releases PPTRH leading to its activation, inhibitors of this PTPRH/CNKSR1 interaction could represent novel drugs for HER2-positive breast cancers. Here, ERBB2 is linked to breast cancer.